El interés en corto de Sonnet BioTherapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Sonnet BioTherapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Sonnet BioTherapeutics (NASDAQ:SONN) Bolsa, Informe de interés en corto

Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics Holdings Inc

Can a cannabis brand go from a garage startup to an acquisition by a multi-state operator in a few years? LEVIA did exactly that. What began as an experiment in cannabis tinctures, brewed above a Massachusetts garage, quickly became one of the state&#8217;s top-selling cannabis beverage brands—selling out before their products even hit the shelves.
For cannabis investors, the LEVIA story isn't just a tale of entrepreneurial grit; it's a roadmap to success in a rapidly growing sector. By focusing on a unique, effects-based product and seizing an untapped opportunity in the market, founders Kristin and Eric Rogers scaled their startup into a high-demand brand that caught the attention of AYR Wellness.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h2 class="wp-block-heading">Can Cannabis Be More Than Smoking?</h2>
Before <a href="https://levia.buzz/products/cannabis-infused-seltzer/">LEVIA</a> was a household name in the Massachusetts cannabis scene, it was a small venture operating out of the Rogers&#8217; garage. Kristin, a substance abuse therapist and Eric, a brand marketer, both saw the potential for cannabis to change lives, particularly as an alternative to harmful substances like alcohol and opioids. 
Their journey began with a simple question: How do we create a cannabis product that doesn't require smoking?
&#8220;My husband started making tinctures using medicinal cannabis, and we realized very quickly this was a thing,&#8221; Kristin said. &#8220;We also picked strains. Eric found medicinal strains that were very specific on what their purpose was.&#8221;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="680" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164644/KRogers-Headshot-3.15.24-680x1024.jpg" alt="" class="wp-image-601646" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164644/KRogers-Headshot-3.15.24-680x1024.jpg 680w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164644/KRogers-Headshot-3.15.24-199x300.jpg 199w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164644/KRogers-Headshot-3.15.24.jpg 717w" sizes="(max-width: 680px) 100vw, 680px" /><figcaption class="wp-element-caption">Kristin Rogers &#8211; LEVIA&#8217;s co-founder. </figcaption></figure>
Their mission was clear: to create consistent, reliable cannabis products that mirrored the predictability of alcohol consumption. LEVIA's first tinctures were alcohol-based, but, they wanted to move away from alcohol-based products.
&#8220;We wanted to help people use cannabis without having to smoke it, and at the same time, we wanted to provide something that could compete with alcohol,&#8221; Kristin told Benzinga. &#8220;The idea was to create a product where you know how you're going to feel, just like when you drink a glass of wine.&#8221;
<h3 class="wp-block-heading">Enter The Beverage Market: Scaling The Dream</h3>
As LEVIA grew, so did the need for a larger, more sophisticated operation. They raised money &#8220;on hopes and dreams&#8221; and managed to retrofit a brewery in Georgetown, <a href="https://www.benzinga.com/topic/massachusetts-cannabis">Massachusetts</a> where they could produce their products on a much larger scale.
Their hard work paid off. LEVIA&#8217;s cannabis seltzers, known for their fast onset, zero calories and zero sugar, quickly captured the attention of consumers. The brand introduced three signature lines—Achieve, Celebrate and Dream—each tailored to specific consumer needs. &#8220;We realized early on that no one was doing effects-based drinks,&#8221; Kristin says. 
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/40886620/how-this-former-dea-consultant-is-making-craft-cannabis-profitable-in-new-jersey-a-dirt-y-little"> How This Former DEA Consultant Is Making Craft Cannabis Profitable In New Jersey: A &#8216;Dirt-y&#8217; Little Secret</a>
<h3 class="wp-block-heading">Building A Brand: Crafting The Perfect Lineup</h3>
When it came time to brand their products, Kristin and Eric honed in on a clean, apothecary-style look, something that conveyed quality and care. But the branding was only one piece of the puzzle. LEVIA's real breakthrough came in narrowing its product line to three drinks. The rationale? Simplicity, clarity and <a href="https://www.benzinga.com/topic/cannabis-marketing">targeting a broad range of consumer needs. </a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="884" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164811/ice3.jpg" alt="" class="wp-image-601649" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164811/ice3.jpg 884w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164811/ice3-259x300.jpg 259w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164811/ice3-768x890.jpg 768w" sizes="(max-width: 884px) 100vw, 884px" /><figcaption class="wp-element-caption">Courtesy of LEVIA</figcaption></figure>
"We started by picking specific strains but quickly realized we couldn't guarantee the same strain every time. So we focused on what most people want to feel." Kristin said.
<h3 class="wp-block-heading">Clean Extraction: LEVIA's Full-Spectrum Advantage</h3>
LEVIA's success is rooted in its full-spectrum products, which contain all the naturally occurring compounds from the cannabis plant—<a href="https://www.benzinga.com/general/biotech/23/10/35300227/from-cbn-cbg-to-thcv-consumer-centric-brands-embrace-rare-cannabinoids-for-differentiation">THC, CBD, CBG and terpenes</a>—creating an enhanced &#8220;entourage effect&#8221; for a more balanced experience.
Using CO2 extraction, one of the cleanest methods, LEVIA ensures its products are potent and pure. This process preserves the plant's natural compounds without leaving harmful solvents. As Kristin puts it, "We're chasing the closest thing we can get to smoking, but without the smoke."
<h2 class="wp-block-heading">It's A Match!&nbsp;</h2>
Within just six months of launching, LEVIA's success was undeniable. The brand's beverages were selling out before they even hit the shelves. This rapid growth caught the attention of larger players in the cannabis space, including multi-state operator AYR Wellness (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>).&nbsp;
&#8220;We were ranked first or second nationally, even though we were only in <a href="https://www.benzinga.com/topic/massachusetts-cannabis">Massachusetts</a>,&#8221; Kristin said. &#8220;AYR had the largest footprint of the companies that approached us, and we saw it as an opportunity to scale.&#8221;
Since the acquisition, Kristin has remained with the company, learning from the broader operations at AYR. &#8220;I've learned so much about different parts of the business that I wouldn't have had the chance to before. It's been an exciting journey.&#8221;
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/40972472/x-rays-microwaves-and-now-what-this-company-freezes-weed-at-320-f-to-kill-mold-and-save-a-ton"> X-Rays, Microwaves And Now What? This Company Freezes Weed At -320°F To Kill Mold And Save A Ton</a>
<h3 class="wp-block-heading">Passion, Innovation, Persistence</h3>
For other cannabis entrepreneurs looking to make their mark in an increasingly competitive market, Kristin offers some valuable advice. &#8220;Be an expert in what you do and approach it with passion. Right now, MSOs [multi-state operators] aren't looking for the same old thing. They want better products or new ways for people to enjoy cannabis.&#8221;
Today, LEVIA continues to lead in the cannabis beverage market, with plans to expand beyond Massachusetts.&nbsp;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="703" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164843/Levia-x3-703x1024.jpg" alt="" class="wp-image-601650" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164843/Levia-x3-703x1024.jpg 703w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164843/Levia-x3-206x300.jpg 206w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164843/Levia-x3.jpg 741w" sizes="(max-width: 703px) 100vw, 703px" /><figcaption class="wp-element-caption">Courtesy of LEVIA. </figcaption></figure>
The brand's popular tinctures have already made their way to states like Florida and Nevada, and Kristin is particularly excited about entering New Jersey. &#8220;There's a camaraderie between Massachusetts and New Jersey, and I'm most looking forward to getting our drinks there next.&#8221;
As for the immediate future, LEVIA has launched its Blood Orange seltzer, a limited-edition flavor timed for Halloween. &#8220;We wanted to do something seasonal, and people love the orange flavor. It&#8217;s been a hit already,&#8221; Kristin said.
Read Next:<a href="https://www.benzinga.com/general/biotech/24/09/40754415/transforming-a-5-000-year-old-craft-how-weed-companies-use-data-to-make-hash-without-losing-its-a"> Transforming A 5,000-Year-Old Craft: How Weed Companies Use Data To Make Hash Without Losing Its Art</a>

Biotech

Cannabis

Market Summary

News

Contracts

Retail Sales

Management

Success Stories

Startups

Exclusives

Markets

Interview

AYRWF

Sold Out Before Hitting Shelves: Why Did AYR Wellness Snatch Up This Local Cannabis Brand?

Ryan Routh, charged with the attempted assassination of former President Donald Trump, has requested the recusal of U.S. District Judge Aileen Cannon from his case, citing potential bias.
What Happened: Routh&#8217;s legal team submitted a request on Thursday for Judge Cannon to step down from the case. They argued that the &#8220;unprecedented circumstances&#8221; surrounding the case could lead to a perception of partiality, given that Trump, who appointed Cannon and has publicly praised her, is the alleged victim, <a href="https://thehill.com/regulation/court-battles/4940160-ryan-routh-trump-assassination-cannon-recuse/">reported</a> The Hill.
Trump, currently running as the Republican presidential candidate against Vice President Kamala Harris, has frequently commended Cannon for her rulings in his case. Routh&#8217;s lawyers contend that if Trump were to be re-elected, he could potentially nominate Cannon for a higher federal judgeship, thereby creating a conflict of interest.
&#8220;By repeatedly and publicly praising this Court by name for its rulings in his case, Mr. Trump has arguably bolstered the perception that the Court is partial in his favor,&#8221; wrote the attorneys of Routh.
Interestingly, Cannon is presiding over both Routh&#8217;s criminal prosecution and the criminal prosecution of Trump by special counsel Jack Smith for allegedly retaining classified documents unlawfully. Cannon dismissed Trump&#8217;s charges in July, a decision Smith is now appealing.
Routh&#8217;s attorneys maintain that federal law necessitates Cannon&#8217;s recusal, given Trump&#8217;s public endorsement of her. Federal prosecutors are currently reviewing the request.
Routh is facing five criminal charges, including the attempted assassination of a major presidential candidate. If found guilty, he could be sentenced to life imprisonment.
See Also: <a href="https://www.benzinga.com/news/24/10/41348822/mark-cuban-says-he-knows-what-trump-wants-to-achieve-with-tariffs-but-the-ex-president-has-no-idea-w?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Says He Knows What Trump Wants To Achieve With Tariffs But The Ex-President Has No Idea What It Takes To Do It — &#8216;That&#8217;s How Crazy His Approach Is&#8217;</a>
Why It Matters: Routh was charged with two federal gun-related offenses in connection with his <a href="https://www.benzinga.com/general/politics/24/09/40882524/man-accused-in-trump-assassination-attempt-could-face-15-years-for-federal-gun-crimes-whats-next">attempted assassination of Trump</a>, marking the second attempt on the former president&#8217;s life ahead of the 2024 election.
Trump was escorted to safety <a href="https://www.benzinga.com/24/09/40869836/donald-trump-safe-and-unharmed-after-shooting-incident-at-florida-golf-club">following a shooting incident</a> at his Florida golf club, as reported by <a href="https://www.benzinga.com/24/09/40869836/donald-trump-safe-and-unharmed-after-shooting-incident-at-florida-golf-club">Benzinga</a>. 
This month, Another man was <a href="https://www.benzinga.com/news/24/10/41306168/man-held-with-loaded-weapon-ne">arrested with loaded firearms</a> near a rally site for Trump in California, possibly preventing a third assassination attempt.
In July, a shooter at a Donald Trump rally in Butler, Pennsylvania was killed, and one attendee died. Trump was led offstage by Secret Service agents while <a href="https://www.benzinga.com/general/politics/24/07/39761947/gunman-dead-trump-rally-attendee-killed-says-local-da-former-president-comes-under-fire-in-penns">bleeding from his ear.</a>
Image via Flickr
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Trump Assasination Suspect Wants Judge Aileen Cannon To Recuse Herself: The Ex-President Has 'Bolstered The Perception That The Court Is Partial In His Favor'

BIOR

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Kintara Therapeutics, Inc. - Common Stock

KTRA

SDOT

SANW

A close head-to-head battle between Donald Trump and Vice President Kamala Harris is expected in polls for the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election.</a>
Betting prediction markets paint a different picture with one candidate jumping out to a sizable lead. Here's the latest.
What Happened: Prediction markets Polymarket and Kalshi are among the companies taking election betting by storm and often showing wide swings on the leading candidate, something that has drawn red flags<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41363075/26m-bet-on-trumps-election-victory-fuels-speculation-of-coordinated-activity-on-polymarket"> in recent weeks.</a>
Polymarket witnessed a wide swing in Trump's favor, which comes with several large wagers placed on him, which could sway the percentage chance he has of winning and not be indicative of how people will vote or who the majority of people think will win.
On Kalshi, Trump is also seeing his lead grow, with the prediction market for the 2024 presidential election winner showing a 58% chance for Trump and 42% chance for Harris on Thursday, hitting a record-high 16-point lead for the former president.
At the time of writing, the market shows Trump at 57% and Harris at 43% with over $22.9 million in wagers. Polymarket shows Trump with a 61% chance of winning and Harris with a 39% chance of winning with a $1.9 billion bet.
Kalshi recently <a href="https://www.benzinga.com/news/24/09/40760283/betting-on-u-s-elections-federal-judges-decision-greenlights-political-wagers" target="_blank" rel="noreferrer noopener">resumed accepting bets&nbsp;</a>on the 2024 election after a federal appeals court lifted a prior ban that came as the Commodity Futures Trading Commission (CFTC) contested the markets.
The company calls itself the only place to legally bet on the election in the U.S., with other prediction markets and sportsbooks not allowed to legally accept wagers in the country.
While prediction markets show Trump as the overall leader, the key markets could be on the individual swing states that could determine the election. 
Here are the current <a href="https://kalshi.com/live/swing-states">odds </a>on Kalshi, with electoral college votes for each state in parentheses:
<ul>
<li>Arizona (11): Trump 64%, Harris 36%</li>
<li>Georgia (16): Trump 60%, Harris 40%</li>
<li>Michigan (15): Harris 51%, Trump 49%</li>
<li>Nevada (6): Harris 52%, Trump 48%</li>
<li>North Carolina (16): Trump 58%, Harris 42%</li>
<li>Pennsylvania (19): Trump 54%, Harris 46%</li>
<li>Wisconsin (10): Trump 52%, Harris 48%</li>
</ul>
The current odds show Harris winning two states and getting 21 electoral college votes from the seven key states and Trump winning five states and getting 72 electoral college votes from the swing states.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent101724">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: On Polymarket, users can deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network, or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). In each betting market, the winning options pays out at $1.
Polymarket could show results that skew to a more international audience, while Kalshi could provide a better look at who American voters think will win.
Both prediction markets differ from national election polls for the overall winner, where Harris is often the winner. Sportsbooks show Trump as<a href="https://www.benzinga.com/general/sports-betting/24/10/41347270/trump-vs-harris-2024-election-polls-sportsbooks-betting-odds-show-different-winners-for-20"> the slight favorite,</a> but much closer than the prediction markets.
A<a href="https://www.benzinga.com/general/politics/24/10/41283673/trump-vs-harris-2024-election-swing-state-poll-too-close-to-call-but-this-candidate-leads"> recent Emerson College poll </a>of voters in the <a href="https://www.benzinga.com/topic/swing-states">seven key swing states </a>showed a similar result to the Kalshi markets above.
<ul>
<li>Arizona: Trump 49%, Harris 47%</li>
<li>Georgia: Trump 49%, Harris 48%</li>
<li>Michigan: Trump 49%, Harris 49%</li>
<li>Nevada: Harris 48%, Trump 47%</li>
<li>North Carolina: Trump 49%, Harris 48%</li>
<li>Pennsylvania: Trump 49%, Harris 48%</li>
<li>Wisconsin: Trump 49%, Harris 49%</li>
</ul>
That poll showed Trump leading in four states, Harris leading in one and the candidates tied in two states. The percentages were much closer than the prediction markets though.
The seven swing states in question together represent 93 electoral votes in the 2024 election. Six of the seven states were won by President Joe Biden in the 2020 election with Trump winning North Carolina. Several of the states were flipped from Trump's win in the 2016 election.
An X account shared an update from election predictor Nate Silver saying Trump has a 50% chance of winning the 2024 election. The model jumps to 93% chance if Trump wins Pennsylvania.
The tweet prompted a response from Tesla CEO Elon Musk who has publicly supported Trump and is now campaigning for him.
"That's why I'm in Pennsylvania," Musk <a href="https://x.com/elonmusk/status/1847000395912302630">said</a>.
Musk <a href="https://x.com/elonmusk/status/1846996928451826093">said </a>"making progress" earlier Thursday when sharing the Kalshi market that showed Trump with an all-time high lead in the prediction market.
The new prediction of the importance of Pennsylvania and its 19 electoral votes and Trump's growing lead in the state could illustrate why the overall presidential race is close.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/24/10/41302431/elon-musk-to-end-year-as-richest-man-in-the-world-prediction-market-says-yes-higher-chance-than-l">Elon Musk To End Year As Richest Man In The World? Prediction Market Says Yes, Higher Chance Than Larry Ellison Or Jensen Huang</a></li>
</ul>
Photo: Shutterstock

$ETH

$MATIC

$USDC

USDC

Trump Vs. Harris Swing State Battle: Musk Says 'That's Why I'm In Pennsylvania' With Kalshi Prediction Market Results On Display

Allstate Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) reported $630 million in catastrophe losses related to Hurricane Helene alone. The company reported total estimated catastrophe losses of $889 million for September, more than twice the amount reported <a href="https://www.benzinga.com/pressreleases/24/10/b41378242/allstate-announces-september-and-third-quarter-2024-catastrophe-losses-run-off-reserve-review-and-">for the same month last year.&nbsp;</a>
What Happened: The impact of Hurricane Helene has led to a substantial increase in Allstate&#8217;s losses for the third quarter of 2024 which the company reported as $1.7 billion, up from $1.18 billion in the same quarter in 2023. 
Other insurance companies affected by the recent hurricanes include Progressive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>), which <a href="https://www.benzinga.com/pressreleases/24/10/g41329804/progressive-reports-september-2024-results">recorded</a> $563 million in catastrophe in September as a result of Hurricane Helene. Travelers Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) reported catastrophe losses of $939 million for the third quarter of 2024 due to Hurricane Helene, an increase of $89 million compared to the same period last year.
Read Next: <a href="https://www.benzinga.com/news/24/10/41385546/ftc-click-to-cancel-rule-makes-it-easy-to-end-subscriptions-what-it-means-for-netflix-planet-fitness">FTC &#8216;Click-To-Cancel&#8217; Rule Makes It Easy To End Subscriptions: What It Means For Netflix, Planet Fitness And More</a>
Moody's Risk Management Solutions, or RMS, said<a href="https://www.benzinga.com/news/24/10/41321615/hurricanes-helene-milton-insurance-losses-spike-to-55b-moodys"> it expects</a> combined total insured losses from Hurricane Helene and Hurricane Milton to range between $35 billion and $55 billion.
According to <a href="https://www.insurtechinsights.com/hurricanes-helene-and-milton-floridas-insurance-market-on-the-brink/">a report</a> from Insurtech Insights, Hurricanes Helene and Milton contributed to total losses for Florida insurers of more than $100 billion for the fifth consecutive year, comparable to the losses from Hurricane Katrina in 2005.&nbsp;
Why It Matters: Citizens, Florida's state-backed insurer of last resort, has seen a surge in policyholders in recent years, especially after recent destructive hurricanes. 
The rapid influx raises serious concerns about its financial stability as it has experienced massive underwriting losses, amounting to hundreds of millions of dollars. Citizens estimates it is currently at a 38% rate inadequate, meaning it needs a 38% rate increase to be solvent. However, Florida law caps its annual rate increases at 10%
Citizens is transferring more than 648,000 policies to private insurers, per<a href="https://www.clickorlando.com/news/local/2024/10/04/what-citizens-insurance-depopulation-means-for-florida-homeowners/"> Click Orlando</a>. These companies are also experiencing <a href="https://www.benzinga.com/markets/equities/24/10/41240852/back-to-back-hurricanes-batter-floridas-insurance-market-stocks-to-watch">financial strain</a> due to increased claims, likely leading to higher premiums and reduced coverage availability.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41346351/cybersecurity-firm-warns-of-threats-to-2024-presidential-election-integrity">Cybersecurity Firm Warns Of Threats To 2024 Presidential Election Integrity</a>&nbsp;</li>
</ul>
Photo: wurliburli from Pixabay

Movers

Insurance

Allstate Records $630M In Losses From Hurricane Helene, Other Insurers Report Significant Losses As Damage Mounts

Merck also announced data from a planned interim analysis of the MK-1654-007 trial, a Phase 3 trial evaluating the safety and efficacy of clesrovimab versus palivizumab in infants and children at increased risk for severe RSV disease.
The primary endpoint of the study is the safety and tolerability of clesrovimab in infants entering their first RSV season. Interim results showed clesrovimab had a comparable safety profile to palivizumab, and no drug-related serious AEs were reported to date.
Incidence rates of RSV-associated MALRI requiring &ge; 1 indicator of LRI or severity and RSV-associated hospitalizations (secondary endpoints) were also comparable between clesrovimab (3.6%&nbsp;and&nbsp;1.3%, respectively) and palivizumab (3.0%&nbsp;and&nbsp;1.5%, respectively) through Day 150 (5 months).

Merck Reports Data From Planned Interim Analysis Of MK-1654-007 Trial; Interim Results Showed Clesrovimab Had Comparable Safety Profile To Palivizumab And No Drug-Related Serious Adverse Events Were Reported To Date

In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than&nbsp;84%&nbsp;and&nbsp;90%, respectively, through 5 months.
Clesrovimab has the potential to become the first and only approved immunization designed to protect infants with the same single dose regardless of weight for the duration of their first RSV season.

Merck Reports Results From Phase 2b/3 Clinical Trial Evaluating Clesrovimab; Results From MK-1654-004 Trial Met All Prespecified Endpoints

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has dominated the electric vehicle sector for years, but is seeing its global market share under pressure in China and other territories with Chinese EV companies <a href="https://www.benzinga.com/markets/equities/24/09/40669363/teslas-china-rivals-report-steady-august-sales-performance-amid-intense-price-competition-what-i">launching low-cost models.</a>
What Happened: Tesla and the <a href="https://www.benzinga.com/electric-vehicles">electric vehicle sector </a>could have another rival soon with Chinese company Skywell unveiling new electric vehicles at the 2024 Paris Auto Show this week.
Skywell may not be a household name in the U.S. yet, but there's a chance that consumers are familiar with the company's Skyworth affordable televisions that are sold in America by Walmart and Amazon.
Skywell unveiled the Q hatchback electric vehicle at the auto show, as <a href="https://electrek.co/2024/10/17/this-maker-of-cheap-tvs-just-launched-a-solid-looking-ev/">reported </a>by Electrek. The vehicle could compete against other similar electric vehicle offerings like the VW ID.3, Cupra Born and BYD Dolphin, according to the report.
The Q is expected to go on sale in 2025 in Europe and be "competitively priced." While not all details have been released, the report notes that a larger battery option available could provide up to 300 miles of range and the 0-60mph time is quicker than the strong-selling BYD Dolphin.
The company best known for its televisions and electronics previously launched the BE11 in the U.K. and sold electric vehicles in Israel previously, Electrek reported.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: While it's early into the Q launch phase, the Electrek report said the vehicle looks to be a potential contender in the electric vehicle space.
While a transition from making affordable televisions to affordable electric vehicles may sound like a stretch, many technology companies have evolved from their early roots.
Electrek shares the examples of BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) previously making mobile phones before cars, and Volvo owner Geely making refrigerator parts before vehicles. Let's not forget that Nintendo got its start as a playing cards company before getting into video games.
How the company got its start shouldn&#8217;t be the concern here for Tesla and other EV makers, the major concern should be the potential lower price point. 
The Skywell vehicle might not hit the market and might never be available for sale in the U.S. The potential release and focus on a lower price point will likely put the potential vehicle in competition with BYD and other Chinese electric vehicle companies.
These Chinese companies continue to put pressure on Tesla's global market share. While Tesla has been competitive on pricing for years thanks to its vertical integration, the company is getting beat in price by several models in the competitive battle for market share and units sold.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41027049/tesla-returns-to-paris-motor-show-for-first-time-in-6-years-cybertruck-to-be-featured-will-elon-musk">Tesla Returns To Paris Motor Show For First Time In 6 Years: Cybertruck To Be Featured, Will Elon Musk Present?</a></li>
</ul>
Photos: Unsplash/Pixabay

Global

BYDDY

TSLA

Tesla Has A New Chinese Electric Vehicle Competitor: How A Company That Used To Sell Cheap TVs Is Entering EV Race

CMCSA

Comcast Installs Its First Flagship Lift Zone In Partnership With Inspiredu In Atlanta, Georgia

The Palliser Block consists of oil and gas wells, surface facilities, a pipeline network and certain oil and gas development rights. The transaction, which is subject to regulatory approval and other customary closing conditions, is expected to close late in the&nbsp;fourth quarter&nbsp;of 2024.

Asset Sales

SLB Agrees To Sell Its Interests In The Palliser Block Located In Alberta, Canada; No Terms Disclosed

&quot;The transition to a facility with competitive power costs, reliable uptime, and continued upgrades to our mining fleet ensures that we are well-positioned for profitability and growth through 2025,&quot; the company said.

Guidance

Sphere 3D Anticipates Strong Bitcoin Market And Remain Focused On Executing Strategic Plan Looking Ahead To Q4 And Into 2025

Mining production decreased in September as the company focused on its long-term strategic goal of transitioning to lower-cost hosting sites. The decrease reflects significant changes at one colocation site, where the hosting provider bought out the company&#39;s contract.
This buyout has strengthened the company&#39;s balance sheet by increasing cash reserves and lowering overall cost of mining. The company is currently evaluating miners from this site and is actively exploring more affordable hosting options.
In line with this strategic shift, the company has recently added 0.21 EH/s of higher-efficiency machines to its fleet. These machines are expected to go live in October, in addition to a total of 1,000 Bitmain S21 units scheduled for energization by Q4 2024 and another 1,000 Bitmain S21s in Q1 2025.

Sphere 3D Reports 9.2 Bitcoin Mined In September 2024, Down From 63.6 Prior Year

Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) reported quarterly earnings of $1.80 per share which missed the analyst consensus estimate of $1.89 by 4.76 percent. This is a 8.63 percent decrease over earnings of $1.97 per share from the same period last year. The company reported quarterly sales of $823.10 million which beat the analyst consensus estimate of $808.19 million by 1.84 percent. This is a 14.93 percent increase over sales of $716.20 million the same period last year.

Earnings

UPDATE: Western Alliance Q3 GAAP EPS $1.80 Misses $1.89 Estimate, Sales $823.10M Beat $808.19M Estimate

To cure defaults, maintain appropriate liquidity and support the Company&#39;s transformation initiatives, Comtech entered into a new&nbsp;$25.0 million&nbsp;subordinated unsecured term loan facility with the existing holders of the Company&#39;s convertible preferred stock.
Within the terms of the amended credit facility, this new subordinated unsecured term loan allows the Company to maintain a consistent level of borrowing capacity.

CMTL

Comtech Reports Delay In Filing Annual Report; Expects Reporting Significantly Lower-Than-Expected Performance, Primarily In Its S&S Segment, In Q4

In connection with the Board&#39;s transformative strategy, the Company has undertaken a detailed evaluation of its S&amp;S portfolio to identify opportunities to divest, separate and/or rationalize businesses or facilities that are not core to Comtech&#39;s go-forward focus.
Consistent with this effort, in its fourth fiscal quarter, Comtech made the decision to exit its subsidiary operations in Basingstoke, United Kingdom.
Taking into consideration the significant ongoing investment as well as unfavorable contract terms on prospective antenna sales, the Board concluded the U.K. business would not generate an attractive return on invested capital and made the decision to exit these operations. After anticipated restructuring charges associated with the exit of the Basingstoke operations, Comtech expects to realize approximately&nbsp;$10 million&nbsp;of annual cash savings.

Comtech Says Working With Independent Advisors To Identify Opportunities To Align Cost Structure; Expects Near-term Restructuring Charges

Comtech Discloses Strategic Alternatives Process For Terrestrial & Wireless Networks Segment; Amends Credit Facility

Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) has outperformed the market over the past 5 years by 2.02% on an annualized basis producing an average annual return of 16.28%. Currently, Brinker International has a market capitalization of $4.00 billion. 
Buying $100 In EAT: If an investor had bought $100 of EAT stock 5 years ago, it would be worth $217.01 today based on a price of $89.30 for EAT at the time of writing.
<h3>Brinker International's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729200662_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Brinker International 5 Years Ago Would Be Worth Today

Sonnet BioTherapeutics Holdings (SONN) has shared an announcement. The Company has partnered with the Sarcoma Oncology Center to further the develo...

Sonnet BioTherapeutics Advances Pancreatic Cancer Drug Trial

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sonnet BioTherapeutics Holdings (SONN – Research Rep...

Analysts' Top Healthcare Picks: Sonnet BioTherapeutics Holdings (SONN), Agilent (A)

The latest update is out from Sonnet BioTherapeutics Holdings ( ($SONN) ). Sonnet BioTherapeutics Holdings, Inc. is set to engage investors with a ...

Sonnet BioTherapeutics to Present at Investor Series

An announcement from Sonnet BioTherapeutics Holdings ( ($SONN) ) is now available. Sonnet BioTherapeutics has successfully finished enrolling parti...

Sonnet BioTherapeutics Advances Solid Tumor Trial

Sonnet BioTherapeutics to execute 1-for-8 reverse stock split

Sonnet BioTherapeutics Holdings ( ($SONN) ) has issued an update. Sonnet BioTherapeutics Holdings, Inc. has partnered with Alkem Laboratories Limit...

Sonnet BioTherapeutics' Strategic Deal to Develop DPN Treatment

Warning: SONN is at high risk of performing badly

Sonnet BioTherapeutics Holdings ( ($SONN) ) has issued an announcement. Sonnet BioTherapeutics Holdings, Inc., a biotech firm specializing in oncol...

Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance

RGLS

SONN

Press Releases

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Comments

Sonnet BioTherapeutics

Interés en corto

Sonnet BioTherapeutics (NASDAQ:SONN) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL